PT2152195E - Produto farmacêutico peptídico para distribuição oral - Google Patents

Produto farmacêutico peptídico para distribuição oral Download PDF

Info

Publication number: PT2152195E
Authority: PT; Portugal
Prior art keywords: oral delivery; peptide pharmaceutical; peptide; pharmaceutical; oral
Prior art date: 2007-05-29

Application number

PT87679361T

Other languages

English (en)

Inventor

Angelo P Consalvo

William Stern

Original Assignee

Enteris Biopharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-29

Filing date

2008-05-29

Publication date

2016-02-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40093991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2152195(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-05-29 Application filed by Enteris Biopharma Inc filed Critical Enteris Biopharma Inc

2016-02-08 Publication of PT2152195E publication Critical patent/PT2152195E/pt

Links

108090000765 processed proteins & peptides Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2235—Secretins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Immunology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physical Education & Sports Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT87679361T 2007-05-29 2008-05-29 Produto farmacêutico peptídico para distribuição oral PT2152195E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US94059807P	2007-05-29	2007-05-29
US12/128,210 US8377863B2 (en)	2007-05-29	2008-05-28	Peptide pharmaceutical for oral delivery

Publications (1)

Publication Number	Publication Date
PT2152195E true PT2152195E (pt)	2016-02-08

Family

ID=40093991

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT87679361T PT2152195E (pt)	2007-05-29	2008-05-29	Produto farmacêutico peptídico para distribuição oral

Country Status (10)

Country	Link
US (6)	US8377863B2 (pt)
EP (2)	EP3009129B1 (pt)
JP (1)	JP5365629B2 (pt)
CN (1)	CN101801309B (pt)
AU (1)	AU2008260615B9 (pt)
CA (1)	CA2689358C (pt)
DK (1)	DK2152195T3 (pt)
ES (1)	ES2560251T3 (pt)
PT (1)	PT2152195E (pt)
WO (1)	WO2008150426A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8088734B2 (en) *	2003-01-21	2012-01-03	Unigene Laboratories Inc.	Oral delivery of peptides
US20050282756A1 (en)	2004-06-18	2005-12-22	Mehta Nozer M	Oral delivery of peptide pharmaceutical compositions
US8377863B2 (en)	2007-05-29	2013-02-19	Unigene Laboratories Inc.	Peptide pharmaceutical for oral delivery
CN102292346B (zh)	2009-01-22	2015-12-02	关键生物科学有限公司	肥胖的治疗
US20120022149A1 (en) *	2010-07-21	2012-01-26	Chowhan Masood A	Pharmaceutical composition with enhanced solubility characteristics
JP5715425B2 (ja) *	2011-01-24	2015-05-07	株式会社ネットステップ	光ネットワークの障害監視検出装置、方法、プログラム及びシステム
AU2012271453B2 (en)	2011-06-15	2017-07-06	Resother Pharma Aps	Anti-inflammatory pharmaceutical products
EP2773365B1 (en)	2011-11-02	2016-07-20	KeyBioscience AG	Peptide analogs for treating diseases and disorders
BR112014010701A2 (pt)	2011-11-02	2020-06-23	Keybioscience Ag	Uso de um peptídeo
US20150133373A1 (en) *	2012-03-28	2015-05-14	Amylin Pharmaceuticals, Llc	Transmucosal delivery of engineered polypeptides
CN104853749A (zh) *	2012-09-17	2015-08-19	塔瑞克斯制药有限公司	血管紧张素的口服制剂
WO2014102741A2 (en)	2012-12-28	2014-07-03	University Of The Witwatersrand, Johannesburg	Pharmaceutical dosage form
WO2014138241A1 (en)	2013-03-05	2014-09-12	Enteris Biopharma, Inc.	Pharmaceuticals for oral delivery
ES2660788T3 (es)	2013-11-14	2018-03-26	Keybioscience Ag	Miméticos de la calcitonina para el tratamiento de enfermedades y trastornos
CN105475588A (zh) *	2014-10-13	2016-04-13	罗盖特公司	包括包衣酸的压制片
GB201500263D0 (en)	2015-01-08	2015-02-25	Keybioscience Ag	Calcitonin analogues for treating diseases and disorders
US9833411B2 (en)	2015-01-12	2017-12-05	Enteris Biopharma, Inc.	Solid oral dosage forms
KR20190038610A (ko) *	2016-08-05	2019-04-08	타우루스 디벨롭먼트 컴퍼니 엘엘씨	실온 안정성 경구 칼시토닌 제제
GB201704429D0 (en)	2017-03-21	2017-05-03	Keybioscience Ag	Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en)	2017-05-18	2017-07-05	Keybioscience Ag	Dual amylin and calcitonin receptor agonists for treating diseases and disorders
CN108065443B (zh) *	2017-12-30	2020-02-28	厦门金达威维生素有限公司	斥水型双包被微胶囊及其制备方法
EP3773475A1 (en) *	2018-04-06	2021-02-17	Cyprumed GmbH	Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
EP3610862A1 (en) *	2018-08-14	2020-02-19	Apillet APS	Novel oral composition
GB201813678D0 (en)	2018-08-22	2018-10-03	Keybioscience Ag	Acylated calcitonin mimetics
GB201813677D0 (en)	2018-08-22	2018-10-03	Keybioscience Ag	Calcitonin mimetics for treating diseases and disorders
IL281393B2 (en)	2018-09-14	2025-02-01	Cara Therapeutics Inc	Oral formulations of kappa opioid receptor agonists
WO2020257260A1 (en)	2019-06-17	2020-12-24	Massachusetts Institute Of Technology	Formulation of peptide loaded liposomes and related applications
CA3171225A1 (en)	2020-03-18	2021-09-23	Bryan R. Wilson	Oligosaccharide formulations of kappa opioid receptor agonists
EP4226918A1 (en)	2022-02-15	2023-08-16	Filip Majewski	Pharmaceutical single dosage form for oral delivery of peptides
EP4536684A1 (en)	2022-06-13	2025-04-16	B.A.I. Laboratories, LLC	Interleukin-13 binding cyclic oligopeptides and methods of use thereof
WO2025037993A1 (en) *	2023-08-13	2025-02-20	Filip Majewski	Dosage form for peptide agents

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3346953A1 (de) *	1983-12-24	1985-08-14	Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg	Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung
US6319685B1 (en)	1984-09-27	2001-11-20	Unigene Laboratories, Inc.	Alpha-amidating enzyme compositions and processes for their production and use
US4708934A (en)	1984-09-27	1987-11-24	Unigene Laboratories, Inc.	α-amidation enzyme
US4849227A (en) *	1986-03-21	1989-07-18	Eurasiam Laboratories, Inc.	Pharmaceutical compositions
US5789234A (en)	1987-08-14	1998-08-04	Unigene Laboratories, Inc.	Expression systems for amidating enzyme
FR2628429B1 (fr) *	1988-03-08	1990-12-28	Transgene Sa	Variants de l'hirudine, leurs utilisations et les procedes pour les obtenir
US5196404B1 (en) *	1989-08-18	1996-09-10	Biogen Inc	Inhibitors of thrombin
AU653026B2 (en)	1991-06-07	1994-09-15	Teikoku Seiyaku Kabushiki Kaisha	Physiologically active polypeptide-containing pharmaceutical composition
US5912014A (en)	1996-03-15	1999-06-15	Unigene Laboratories, Inc.	Oral salmon calcitonin pharmaceutical products
ATE484572T1 (de)	1997-04-16	2010-10-15	Unigene Lab Inc	Direkte expression von peptiden ins kulturmedium
UA53716C2 (uk) *	1997-06-25	2003-02-17	Пфайзер Продактс Інк.	Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
US20010055648A1 (en) *	1999-12-14	2001-12-27	Primera Foods Corporation	Apparatus and process for coating particles
EP1251867A4 (en)	2000-02-04	2004-12-08	Unigene Lab Inc	NASAL CALCITON INFORMATION
US6673574B2 (en)	2000-11-30	2004-01-06	Unigene Laboratories Inc.	Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en)	2001-03-08	2008-01-08	Unigene Laboratories, Inc.	Oral peptide pharmaceutical dosage form and method of production
US8088734B2 (en)	2003-01-21	2012-01-03	Unigene Laboratories Inc.	Oral delivery of peptides
US20050123507A1 (en)	2003-06-30	2005-06-09	Mahmoud Ameri	Formulations for coated microprojections having controlled solubility
US20050215476A1 (en)	2004-01-21	2005-09-29	Unigene Laboratories Inc.	Amidated parathyroid hormone fragments and uses thereof
US8227241B2 (en)	2004-03-12	2012-07-24	Unigene Laboratories, Inc.	Bacterial host cell for the direct expression of peptides
KR20050104152A (ko)	2004-04-28	2005-11-02	최승호	경구용 약물의 흡수를 증진하는 약제학적 조성물
US20050282756A1 (en)	2004-06-18	2005-12-22	Mehta Nozer M	Oral delivery of peptide pharmaceutical compositions
US7445911B2 (en)	2004-11-24	2008-11-04	Unigene Laboratories Inc.	Enzymatic reactions in the presence of keto acids
JP4856177B2 (ja)	2005-06-24	2012-01-18	ユニジーン・ラボラトリーズ・インコーポレーテッド	アミド化生成物の調製に有用な酵素を発現させるための細胞株
US8093207B2 (en)	2005-12-09	2012-01-10	Unigene Laboratories, Inc.	Fast-acting oral peptide pharmaceutical products
US8377863B2 (en)	2007-05-29	2013-02-19	Unigene Laboratories Inc.	Peptide pharmaceutical for oral delivery
US20120071410A1 (en)	2010-09-21	2012-03-22	Unigene Laboratories Inc.	Calcitonin products and therapies for treating inflammatory or degenerative diseases
AU2012271453B2 (en)	2011-06-15	2017-07-06	Resother Pharma Aps	Anti-inflammatory pharmaceutical products
WO2014138241A1 (en)	2013-03-05	2014-09-12	Enteris Biopharma, Inc.	Pharmaceuticals for oral delivery

2008
- 2008-05-28 US US12/128,210 patent/US8377863B2/en active Active
- 2008-05-29 WO PCT/US2008/006804 patent/WO2008150426A1/en not_active Ceased
- 2008-05-29 DK DK08767936.1T patent/DK2152195T3/en active
- 2008-05-29 EP EP15193178.9A patent/EP3009129B1/en not_active Not-in-force
- 2008-05-29 EP EP08767936.1A patent/EP2152195B1/en active Active
- 2008-05-29 PT PT87679361T patent/PT2152195E/pt unknown
- 2008-05-29 ES ES08767936.1T patent/ES2560251T3/es active Active
- 2008-05-29 JP JP2010510341A patent/JP5365629B2/ja active Active
- 2008-05-29 AU AU2008260615A patent/AU2008260615B9/en not_active Ceased
- 2008-05-29 CN CN2008800182888A patent/CN101801309B/zh active Active
- 2008-05-29 CA CA2689358A patent/CA2689358C/en active Active
2011
- 2011-10-27 US US13/283,055 patent/US8513183B2/en active Active
2012
- 2012-06-04 US US13/487,784 patent/US8664178B2/en not_active Expired - Fee Related
- 2012-06-04 US US13/487,856 patent/US8592366B2/en not_active Expired - Fee Related
2014
- 2014-01-17 US US14/158,029 patent/US9399017B2/en active Active
2016
- 2016-06-06 US US15/174,417 patent/US20160339081A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2560251T3 (es)	2016-02-18
EP2152195B1 (en)	2015-11-11
US8513183B2 (en)	2013-08-20
US20090317462A1 (en)	2009-12-24
CN101801309B (zh)	2013-05-08
EP2152195A1 (en)	2010-02-17
CA2689358A1 (en)	2008-12-11
EP3009129B1 (en)	2017-08-09
US8377863B2 (en)	2013-02-19
US8664178B2 (en)	2014-03-04
US20120315325A1 (en)	2012-12-13
US20130034600A1 (en)	2013-02-07
JP5365629B2 (ja)	2013-12-11
AU2008260615A1 (en)	2008-12-11
AU2008260615B9 (en)	2011-10-13
JP2010529018A (ja)	2010-08-26
DK2152195T3 (en)	2016-02-15
US20160339081A1 (en)	2016-11-24
EP3009129A1 (en)	2016-04-20
AU2008260615B2 (en)	2011-10-06
US20140335169A1 (en)	2014-11-13
US9399017B2 (en)	2016-07-26
CN101801309A (zh)	2010-08-11
US20120040000A1 (en)	2012-02-16
US8592366B2 (en)	2013-11-26
CA2689358C (en)	2012-11-27
WO2008150426A1 (en)	2008-12-11
EP2152195A4 (en)	2012-10-31

Publication	Publication Date	Title
PT2152195E (pt)	2016-02-08	Produto farmacêutico peptídico para distribuição oral
IL206159A0 (en)	2010-12-30	Oral pharmaceutical dosage forms
EP2143424A4 (en)	2013-07-31	ORAL PHARMACEUTICAL PREPARATION FOR SPECIFIC DELIVERY TO THE COLON
IL198911A0 (en)	2010-02-17	Drug delivery
GB0603252D0 (en)	2006-03-29	Dissolution aids for oral peptide delivery
PL2399579T3 (pl)	2013-12-31	Farmaceutyczne postacie dawkowania
IL224505A (en)	2016-03-31	Device for administering drugs
ZA201002014B (en)	2010-11-24	Drug delivery system
PL2059260T3 (pl)	2014-03-31	Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego
GB0621901D0 (en)	2006-12-13	Medicine delivery apparatus
EP1980271A4 (en)	2012-04-25	MEDICINE FOR TRANSNASAL ADMINISTRATION
IL219001A0 (en)	2012-05-31	Drug delivery device
IL183295A0 (en)	2007-12-03	Drug delivery device
IL227899A0 (en)	2013-09-30	Mixing properties for a drug release system
EP2010162A4 (en)	2013-01-09	COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT
EP2226071A4 (en)	2011-06-01	COMPOSITIONS FOR ORAL ADMINISTRATION
ZA201105572B (en)	2012-09-26	Pharmaceutical composition for oral administration
IL205952A0 (en)	2010-11-30	Protease variants for pharmaceutical use
EP1858493A4 (en)	2010-12-01	SYSTEM FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS
IL195822A0 (en)	2009-09-01	Segmented pharmaceutical dosage forms
ZA200908993B (en)	2010-09-29	Oral pharmaceutical solutions containing telbivudine
IL198160A0 (en)	2009-12-24	Pharmaceutical formulations
ZA201102405B (en)	2012-06-27	Pharmaceutical composition for oral administration
EP2197454A4 (en)	2012-07-04	PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES
ZA200810270B (en)	2009-12-30	Segmented pharmaceutical dosage forms